Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573239 | 1.00 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL5473239 | 1.00 | BTK (0.55) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14270420 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL22334237 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL13337688 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL2988884 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14261648 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14270414 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL14261646 | 0.91 | BTK (0.62) | BTKKDM1AMAOBCTSKGAA | |
| SCHEMBL10343938 | 0.89 | BTK (0.61) | BTKKDM1AMAOBCTSKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | Redona Therapeutics, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | LIGACHEM BIOSCIENCES INC. (KR) | 2025-08-19 | — | — | US | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025067111-A1 | MENIN-MLL INTERACTION INHIBITOR AND PREPARATION METHOD THEREFOR, AND APPLICATION | 苏州必扬医药科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230365509-A1 | BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER | Redona Therapeutics, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20110082132-A1 | [4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-07 | — | — | US | disclosed |
| EP-2297107-A1 | Ý4-(1-AMINO-ETHYL) -CYCLOHEXYL¨-METHYL-AMINE AND Ý6-(1-AMINO-ETHYL) -TETRAHYDRO- PYRAN-3-YL¨-METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| WO-2010032856-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009147616-A1 | [4-(1-AMINO-ETHYL) -CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-ETHYL) -TETRAHYDRO- PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-10 | — | — | WO | disclosed |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | MERCK & CO., INC. (US) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | BTK 1928/4885KDM1A 3365/4885MAOB 273/4885 |
| US-20110082132-A1 | [4-(1-AMINO-EHTYL) - CYCLOHEXYL] -METHYL-AMINE AND [6-(1-AMINO-EHTYL) -TETRAHYDRO-PYRAN-3-YL] -METHYL-AMINE DERIVATIVES AS ANTIBACTERIALS | DOT1L, EHMT1, Q6ZSR9 | BTK 2385/4885KDM1A 90/4885MAOB 399/4885 |
| US-20230365509-A1 | BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER | H1-10, H1-3, H1-0 | BTK 337/4885KDM1A 247/4885MAOB 20/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | BTK 3002/4885KDM1A 1410/4885MAOB 1610/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | BTK 3650/4885KDM1A 3776/4885MAOB 1677/4885 |
| US-12391690-B2 | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | ENPP2, PLA2G10, LPCAT1 | BTK 2477/4885KDM1A 3059/4885MAOB 1446/4885 |
| US-12583825-B2 | Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer | H1-3, RB1, H1-2 | BTK 54/4885KDM1A 180/4885MAOB 357/4885 |
| US-20080076783-A1 | Cycloalkyl Keto Piperidine Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | BTK 4766/4885KDM1A 1021/4885MAOB 1274/4885 |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | BTK 166/4885KDM1A 122/4885MAOB 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.